Evidence map›Paper›PMID 25905725›Full record

ArticlePloS one2015

The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model.

Viviane D Lima, Isabell Graf, Curt G Beckwith, Sandra Springer, Frederick L Altice, Daniel Coombs, Bryan Kim, Brian Kim, Lauren Messina, Julio S G Montaner and 1 more

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Prevalence and Management of Sexually Transmitted Infections in Correctional Settings: A Systematic Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Viviane D LimaBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Department of Medicine, Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Isabell GrafDepartment of Mathematics, Simon Fraser University, Burnaby, Canada.
Curt G BeckwithAlpert Medical School of Brown University, The Miriam Hospital, Providence, Rhode Island, United States of America.
Sandra SpringerYale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, Connecticut, United States of America.
Frederick L AlticeYale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, Connecticut, United States of America; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, New Haven, Connecticut, United States of America.
Daniel CoombsDepartment of Mathematics, University of British Columbia, Vancouver, British Columbia, Canada.
Bryan Kim
Brian KimRollins School of Public Health Department of Epidemiology, Emory University School of Medicine, Atlanta, United States of America.
Lauren MessinaRollins School of Public Health Department of Epidemiology, Emory University School of Medicine, Atlanta, United States of America.
Julio S G MontanerBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Department of Medicine, Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Anne SpauldingRollins School of Public Health Department of Epidemiology, Emory University School of Medicine, Atlanta, United States of America.

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
Prison Interventions and HIV Prevention CollaborationR01DA029910 · NIDA · YALE UNIVERSITY · PI FREDERICK LEWIS ALTICE · 2010 to 2026
$7.9M
Expanding Medication Assisted Therapy in Ukraine (ExMAT)R01DA033679 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2012 to 2021
$6.4M
Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersR01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2007 to 2016
$5.8M
Naltrexone for Opioid Dependent Released HIV+ Criminal Justice PopulationsR01DA030762 · NIDA · YALE UNIVERSITY · PI SPRINGER, SANDRA ANN · 2010 to 2015
$4.1M
HIV, Buprenorphine, and the Criminal Justice SystemR01DA030768 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2010 to 2015
$4.0M
Seek and Treat for Optimal Prevention of HIV & AIDS (STOP HIV/AIDS) in BCR01DA036307 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MONTANER, JULIO SERGIO GONZALEZ · 2013 to 2017
$3.0M
Intervention of HIV, Drug Use and the Criminal Justice System in MalaysiaR01DA025943 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2008 to 2012
$2.7M
A Randomized Trial of Continued Methadone Maintenance vs. Detoxification in JailR01DA027211 · NIDA · MIRIAM HOSPITAL · PI RICH, JOSIAH D · 2009 to 2013
$2.5M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Medication Assisted Therapy as a Conduit to Care for HIV+ CJS Populations TransitK02DA032322 · NIDA · YALE UNIVERSITY · PI SPRINGER, SANDRA ANN · 2011 to 2022
$1.3M
CIHR 125948-1CIHR 129971-1CIHR MOP-125948NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI050409NIDA NIH HHS DA036307NIDA NIH HHS K02 DA032322NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA021525NIDA NIH HHS R01 DA025943NIDA NIH HHS R01 DA027211NIDA NIH HHS R01 DA029910NIDA NIH HHS R01 DA030762NIDA NIH HHS R01 DA030768NIDA NIH HHS R01 DA033679NIDA NIH HHS R01 DA036307NIDA NIH HHS R01 DA27211NIDA NIH HHS R03 DA033851
6 · The paper itself

Abstract

backgroundAnnually, 10 million adults transition through prisons or jails in the United States (US) and the prevalence of HIV among entrants is three times higher than that for the country as a whole. We assessed the potential impact of increasing HIV Testing/Treatment/Retention (HIV-TTR) in the community and within the criminal justice system (CJS) facilities, coupled with sexual risk behavior change, focusing on black men-who-have-sex-with-men, 15-54 years, in Atlanta, USA.

methodsWe modeled the effect of a HIV-TTR strategy on the estimated cumulative number of new (acquired) infections and mortality, and on the HIV prevalence at the end of ten years. We additionally assessed the effect of increasing condom use in all settings.

resultsIn the Status Quo scenario, at the end of 10 years, the cumulative number of new infections in the community, jail and prison was, respectively, 9246, 77 and 154 cases; HIV prevalence was 10815, 69 and 152 cases, respectively; and the cumulative number of deaths was 2585, 18 and 34 cases, respectively. By increasing HIV-TTR coverage, the cumulative number of new infections could decrease by 15% in the community, 19% in jail, and 8% in prison; HIV prevalence could decrease by 8%, 9% and 7%, respectively; mortality could decrease by 20%, 39% and 18%, respectively. Based on the model results, we have shown that limited use and access to condoms have contributed to the HIV incidence and prevalence in all settings.

conclusionsAggressive implementation of a CJS-focused HIV-TTR strategy has the potential to interrupt HIV transmission and reduce mortality, with benefit to the community at large. To maximize the impact of these interventions, retention in treatment, including during the period after jail and prison release, and increased condom use was vital for decreasing the burden of the HIV epidemic in all settings.

Indexed as

Black or African AmericanHomosexuality, MaleAIDS SerodiagnosisGeorgiaHIV InfectionsHumansMaleModels, Theoretical

Identifiers

PMID25905725
PMCPMC4408043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.